Covid19 Vaccine and Lung Immunopathology
As an expanded number of coronavirus vaccines enter human clinical trials, in addition to understanding their efficacy in preventing severe SARS-CoV-2-related disease, a key outcome that will be receiving outsized scrutiny will be whether these vaccines contribute to lung immunopathology upon natural viral infection. Since the emergence of life-threatening severe acute respiratory syndrome (SARS) almost 20 years ago and subsequently Middle East respiratory syndrome (MERS) in 2012, numerous vaccines have been developed and tested in experimental animals to combat these lethal coronavirus-associated respiratory syndromes. An unexpected and concerning feature of several of these is the appearance of lung immunopathology that is seen in animals receiving certain types of vaccines. This result is especially concerning given that vaccine associated enhanced respiratory disease (VAERD) was seen in human vaccine trials against the ubiquitous airway pathogen respiratory syncytial virus (RSV).
Related Conference of Covid19 Vaccine and Lung Immunopathology
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Covid19 Vaccine and Lung Immunopathology Conference Speakers
Recommended Sessions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Alpha 1 Antitrypsin Deficiency & COPD
- Cardiopulmonary Disorders
- Clinical management of severe acute respiratory infection
- COVID-19 Treatment and Recovery
- Covid19 Vaccine and Lung Immunopathology
- Cystic Fibrosis
- Depression and anxiety in COPD
- Diagnosis and Treatment of COPD
- Digital Health in Respiratory Care
- Effect of COVID-19 on Lungs
- Genetic risk factor of COPD
- Idiopathic Pulmonary Fibrosis
- Innate Immunity and Lung Fibrosis
- Investigational Drugs and Other Therapies in the treatment of Respiratory Disease
- Lung cancer
- Lung Cancer Diagnosis & Treatment
- Pathology and Clinical Management of COPD
- Pneumonia
- Pulmonary Rehabilitation
- Respiratory Diseases
- Severe Acute Respiratory Syndrome (SARS)
- Sleep apnea
- Tuberculosis
Related Journals
Are you interested in
- Allergy testing and treatment in respiratory diseases - Euro Pulmonology 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Bronchial thermoplasty for asthma management - Euro Pulmonology 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic cough evaluation and treatment strategies - Euro Pulmonology 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and its impact on respiratory health - Euro Pulmonology 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Genetics of respiratory diseases and precision medicine - Euro Pulmonology 2024 (France)
- Imaging techniques in pulmonary medicine - Euro Pulmonology 2024 (France)
- Interstitial lung disease and lung transplant outcomes - Euro Pulmonology 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung cancer and personalized medicine approaches - Euro Pulmonology 2024 (France)
- Lung cancer screening and early detection programs - Euro Pulmonology 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung microbiome and respiratory diseases - Euro Pulmonology 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Non-invasive ventilation techniques and outcomes - Euro Pulmonology 2024 (France)
- Occupational asthma and work-related respiratory diseases - Euro Pulmonology 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pulmonary arterial hypertension diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary drug delivery systems and innovations - Euro Pulmonology 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary edema pathophysiology and treatment - Euro Pulmonology 2024 (France)
- Pulmonary embolism diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary rehabilitation in critically ill patients - Euro Pulmonology 2024 (France)
- Pulmonary sarcoidosis diagnosis and treatmen - Euro Pulmonology 2024 (France)
- Respiratory failure management in ICU patients - Euro Pulmonology 2024 (France)
- Respiratory syncytial virus updates and management - Euro Pulmonology 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)